"Step change" Yervoy from BMS not cost effective for NICE: may need biomarker test
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has recognised Bristol-Myers Squibb's Yervoy (ipilimumab) as a "step change" in the treatment of advanced melanoma, according to draft guidance published on 14 October. Despite this, Yervoy would not be a cost-effective use of NHS resources due to uncertainty over its long-term benefits and, in the absence of a biomarker, the patient populations it could help, says the institute.